Narayana Hrudayalaya (NH) - PIT Equity Research Analysis

1. Industry Context & Quality Gate

• Industry Structure: Private healthcare providers operate in a capital-intensive environment with multi-year payback periods (3-5 years to break even on greenfield hospitals). Private healthcare in India grows at a structural CAGR of 12-14% due to under-penetration and rising insurance coverage.
• Quality Metrics: ROCE stands at 20.0%, passing the quality gate. D/E ratio is 0.76 with ₹1,970 Cr debt supporting heavy inorganic and organic capex. Promoter holding is stable at 63.3%.

2. Ramp-Aware Catalyst Impact Math

• Event Context: The presentation details Q1 FY27 performance where consolidated revenue grew 78% YoY to ₹2,683.6 Cr. This is driven primarily by the consolidation of the UK acquisition (GBP 65.0M revenue in Q1) and ongoing domestic expansion (+5.3% bed capacity to 6,269 beds).
• Already Priced In: YES. The exact revenue (₹2,684 Cr) and UK consolidation details were disclosed 3 days prior on July 31, 2026 in the Q1 FY27 earnings release.
• Revenue Impact: TTM revenue of ₹7,896 Cr will step up to ~₹10,500-11,000 Cr in Year 1 (~34% annual uplift) as UK operations are fully consolidated. Over a 3-year steady-state horizon, capacity additions in Bengaluru, Kolkata, and Cayman will lift annual revenues by ~48%.
• Earnings Impact: Consolidated EBITDA margins fell from historical ~22-23% to 18.8% due to lower-margin UK assets and ₹20.1 Cr Q1 gestation loss in insurance (NHIC). Assuming UK margins ramp up and insurance losses cap out, steady-state EPS can grow ~30% over 24-36 months.

3. Valuation & Scenario Calibration

• Valuation: Trading at 48.6x trailing P/E against a peer median of 69.5x (e.g., Apollo, Fortis, KIMS). While not cheap, it trades at a discount to peers despite superior ROCE.
• Base Case (+35%): UK margins improve to ~20%, India hospitals maintain 24%+ EBITDA margins, and insurance losses narrow. Market cap expands toward ₹52,900 Cr.
• Bull Case (+65%): Fast UK margin turn-around to 22%, rapid bed fill in Cayman Bay & India greenfields, and insurance arm achieving operational breakeven early.
• Bear Case (-20%): Prolonged margin drag from UK acquisitions, escalating insurance underwriting losses, and regulatory pricing caps on procedures in India.

4. Verdict Rationale

NH is a high-quality healthcare compounder with strong ROCE (20%). The 78% revenue jump marks a major scale transition, but near-term margin compression and gestation drag in insurance/UK cap near-term re-rating. Given that this catalyst was formally released 3 days prior, it is largely priced in near-term, yielding a POSSIBLE multibagger verdict over a 3-year horizon.